Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Marck McLellan: An 'A' for Advancing Expectations

Oct 1, 2011

Marck McClellan, MD, Director, Engelberg Center for Health Reform, Brookings Institute

Rebates and Reform

Sep 1, 2011

User-fee renewal legislation sets the stage for new policies affecting reimbursement, research, and regulatory oversight.

The Supremes Shape Pharma

Aug 1, 2011

A number of important decisions from the Supreme Court will affect drug marketing, research, and regulation

Battles over Biosimilars

Jul 1, 2011

Sponsors must handle interchangeability, exclusivity, cost and coverage hurdles to win biosimilars game

Educating Physicians

Jun 1, 2011

FDA's opiod REMS implies there is still value in industry-sponsored CME

Outrage Over Drug Prices

May 1, 2011

Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies

Revisiting Reform

Apr 1, 2011

Courts, Congress review policies and programs shaping drug costs and access

New Tools Track Safety, Value in Medicine

Mar 1, 2011

FDA's Sentinel Initiative raises broader questions about tapping patient information and health IT for comparative studies in drug development

Challenges, Changes, Commitments

The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
Feb 1, 2011

The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency

ADVERTISEMENT

Click here